Clear Eyes

Search documents
Prestige Consumer Healthcare (PBH) FY Conference Transcript
2025-06-11 15:30
Prestige Consumer Healthcare (PBH) FY Conference June 11, 2025 10:30 AM ET Speaker0 Good morning, everyone, and thank you for joining us at Oppenheimer's twenty fifth Annual Consumer Growth and Ecommerce Conference. My name is Rupesh Parikh. I'm the senior food, grocery, and consumer products analyst here at Oppenheimer. I'm happy to introduce our next presenting company, Prestige Consumer Healthcare. Joining us today are CEO, Ron Lombardi and VP, IR, and Treasury, Phil Turpolili. Prestige sells and distrib ...
Prestige Consumer Healthcare (PBH) FY Earnings Call Presentation
2025-06-11 13:39
Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, and free cash flow; the Company's reinvestment in Clear Eyes as supply increases; the Company's ability to execute on its brand- building strategy and to drive free cash flow and maximize shareholder value; e-commerce ...
Prestige sumer Healthcare (PBH) - 2025 Q4 - Earnings Call Transcript
2025-05-08 13:30
Prestige Consumer Healthcare (PBH) Q4 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 and thank you for standing by. Welcome to the Prestige Consumer Healthcare's Fourth Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Phil Turpoli, Vice ...
Prestige sumer Healthcare (PBH) - 2025 Q4 - Earnings Call Presentation
2025-05-08 11:28
Full-Year Fiscal 2025 Results May 8th, 2025 Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, and free cash flow; the Company's reinvestment in Clear Eyes as supply increases; the Company's ability to execute on its brand- building strategy and to drive free cash flo ...